Search

Curcumin (Cur) considered as a golden nutraceutical, is emerging as one of bioactive compounds demonstrating the most promising biological activities, including antioxidant, antibacterial, anti-inflammatory, anticancer. It is also used for coloring and seasoning in foods. However, Cur applications are limited due to factors like low aqueous solubility, poor colloidal stability and bioavailability. Extensive efforts were made using pure zein (Ze) to develop nanoparticles (NPs) for encapsulation of Cur to overcome the aforementioned issues. Nevertheless, zein nanoparticles (ZeNPs) have limitations related to their instability to neutral pH and rapid degradation by gastric proteases. Thus, the combination between Ze and different biopolymers to produce zein nanocomposites (ZeNCs) for improving the stability of ZeNPs were scrutinized in this study. The mass ratio of Ze/polymer played a critical in the formation and stability of ZeNCs. Electrostatic attraction, hydrogen bonding and intermolecular interaction were responsible for ZeNCs formation. High encapsulation efficiency (EE), storage stability, solubility, bioaccessibility, intestinal permeability and antioxidant activity (AA) for Cur were achieved in ZeNCs compared to ZeNPs. ZeNCs did not show toxicity towards normal NCM460 and 293 cells, but potent anticancer activity against MCF-7, HepG2, Hela, and HCT 116 cells. ZeNCs displayed potential applications in different food matrices. [ABSTRACT FROM AUTHOR]

Traditionally, diverse natural bioactive compounds (polyphenols, proteins, fatty acids, dietary fibers) are used as inhibitors of starch digestive enzymes for lowering glycemic index (GI) and preventing type 2 diabetes mellitus (T2DM). In recent years, organic nanomaterials (ONMs) have drawn a great attention because of their ability to overcome the stability and solubility issues of bioactive. This review aimed to elucidate the implications of ONMs in lowering GI and as encapsulating agents of enzymes inhibitors. The major ONMs are presented. The mechanisms underlying the inhibition of enzymes, the stability within the gastrointestinal tract (GIT) and safety of ONMs are also provided. As a result of encapsulation of bioactive in ONMs, a more pronounced inhibition of enzymes was observed compared to un-encapsulated bioactive. More importantly, the lower the size of ONMs, the higher their inhibitory effects due to facile binding with enzymes. Additionally, in vivo studies exhibited the potentiality of ONMs for protection and sustained release of insulin for GI management. Overall, regulating the GI using ONMs could be a safe, robust and viable alternative compared to synthetic drugs (acarbose and voglibose) and un-encapsulated bioactive. Future researches should prioritize ONMs in real food products and evaluate their safety on a case-by-case basis. [ABSTRACT FROM AUTHOR]

To assess the effectiveness of electroacupuncture (EA) with rehabilitation training in reducing limb spasticity in post-stroke patients. A systematic review was performed by electronically searching six databases (Medline/Pubmed, Embase, Cochrane Library, China National Knowledge Infrastructure, Database for Chinese Technical Periodicals, and Wanfang Data) for randomized controlled trials (RCTs) on EA with rehabilitation training for limb spasticity reduction in post-stroke patients from 1 January 2009 to 1 January 2019. A meta-analysis was performed using SAS 9.3 and RevMan 5.3 software after bibliography screening, data extraction, and risk of bias assessment using the Cochrane handbook. The primary outcome was spasticity. A total of 31 RCTs (including 2488 participants) were included. Except for Cai et al.'s study, the quality of other RCTs was not high. All studies performed a descriptive analysis, and 29 RCTs conducted a meta-analysis. The odds ratio (OR) for marked efficiency was 2.35 (95% confidence interval [CI] 1.68–3.27, Z = 5.03, P <.00001). The OR for Modified Ashworth Scale (MAS) classification was 2.42 (95% CI 1.89–3.10, Z = 7.03; P <.00001). The weighted mean difference (WMD) for MAS score was −0.68 (95% CI −0.79 – −0.56, Z = 11.24, P <.00001). The WMD for clinical spasticity index score was −1.50 (95% CI −2.28 – −0.72, Z = 3.79, P =.0002). EA with rehabilitation training could be a good strategy for reducing limb spasticity after stroke and is better than EA alone or rehabilitation training alone. However, its effectiveness remains to be further verified by large-sample and high-quality RCTs. [ABSTRACT FROM AUTHOR]